Ocugen (OCGN) Competitors

Ocugen (NASDAQ:OCGN) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Does the media refer more to OCGN or MRNA?

In the previous week, Moderna had 28 more articles in the media than Ocugen. MarketBeat recorded 31 mentions for Moderna and 3 mentions for Ocugen. Moderna's average media sentiment score of 0.89 beat Ocugen's score of 0.72 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	17 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Do analysts prefer OCGN or MRNA?

Ocugen currently has a consensus target price of $6.00, suggesting a potential upside of 471.43%. Moderna has a consensus target price of $42.88, suggesting a potential upside of 75.24%. Given Ocugen's stronger consensus rating and higher probable upside, equities research analysts plainly believe Ocugen is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Moderna	4 Sell rating(s)	16 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.04

Which has better valuation and earnings, OCGN or MRNA?

Ocugen has higher earnings, but lower revenue than Moderna. Ocugen is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.05M	75.78	-$54.05M	-$0.20	-5.25
Moderna	$3.24B	2.94	-$3.56B	-$7.53	-3.25

Is OCGN or MRNA more profitable?

Moderna has a net margin of -94.31% compared to Ocugen's net margin of -1,197.71%. Moderna's return on equity of -25.96% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	-1,197.71%	-255.25%	-86.79%
Moderna	-94.31%	-25.96%	-20.09%

Which has more volatility & risk, OCGN or MRNA?

Ocugen has a beta of 3.84, meaning that its share price is 284% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500.

Do institutionals & insiders have more ownership in OCGN or MRNA?

10.3% of Ocugen shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 4.4% of Ocugen shares are held by insiders. Comparatively, 11.0% of Moderna shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Moderna beats Ocugen on 10 of the 16 factors compared between the two stocks.